{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:06:31Z","timestamp":1788303991216,"version":"build-2803163510"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>This review focuses on the characteristics of vitiligo with an emphasis on diagnosis and treatment options. Vitiligo is a chronic skin disease affecting approximately 0.4% of the world\u2019s population. It can lead to stigmatization and a decrease in quality of life. The diagnosis is often straightforward, but there are many other skin conditions which can cause loss of pigmentation. The treatment options have been scarce until 2022 when the first treatment was approved, and today several other treatments are in clinical trials.<\/jats:p>","DOI":"10.61409\/v10240662","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T06:32:37Z","timestamp":1743575557000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["Vitiligo"],"prefix":"10.61409","author":[{"given":"Morten Bahrt Haulrig","family":"Haulrig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Idorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Millington GWM, Levell NJ. Vitiligo: the historical curse of depigmentation. Int J Dermatol. 2007;46(9):990-5. https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03195.x","DOI":"10.1111\/j.1365-4632.2007.03195.x"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kopera D. Historical aspects and definition of vitiligo. Clin Dermatol. 1997;15(6):841-3. https:\/\/doi.org\/10.1016\/S0738-081X(97)00124-7","DOI":"10.1016\/S0738-081X(97)00124-7"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ezzedine K, Eleftheriadou V, Jones H et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757-774. https:\/\/doi.org\/10.1007\/s40257-021-00631-6","DOI":"10.1007\/s40257-021-00631-6"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Akl J, Lee S, Ju HJ et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health. 2024;9(6):e386-e396. https:\/\/doi.org\/10.1016\/S2468-2667(24)00026-4","DOI":"10.1016\/S2468-2667(24)00026-4"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Haulrig MB, Al\u2010Sofi R, Baskaran S et al. The global epidemiology of vitiligo: a systematic review and meta\u2010analysis ofthe incidence and prevalence. J Eur Acad Dermatology Venereol. 2024;3(5):1410-9. https:\/\/doi.org\/10.1002\/jvc2.526","DOI":"10.1002\/jvc2.526"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. https:\/\/doi.org\/10.1016\/S0140-6736(14)60763-7","DOI":"10.1016\/S0140-6736(14)60763-7"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571-592. https:\/\/doi.org\/10.1159\/000506103","DOI":"10.1159\/000506103"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157-1164. https:\/\/doi.org\/10.1111\/ijd.14055","DOI":"10.1111\/ijd.14055"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Faraj S, Kemp EH, Gawkrodger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol. 2022;207(1):27-43. https:\/\/doi.org\/10.1093\/cei\/uxab002","DOI":"10.1093\/cei\/uxab002"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Seneschal J, Boniface K, D'Arino A, Picardo M. An update on vitiligo pathogenesis. Pigment Cell Melanoma Res. 2021;34(2):236-243. https:\/\/doi.org\/10.1111\/pcmr.12949","DOI":"10.1111\/pcmr.12949"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Sosa JJ, Currimbhoy SD, Ukoha U et al. Confetti-like depigmentation: a potential sign of rapidly progressing vitiligo. J Am Acad Dermatol. 2015;73(2):272-5. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.014","DOI":"10.1016\/j.jaad.2015.05.014"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Hann SK, Kim YS, Yoo JH, Chun YS. Clinical and histopathologic characteristics of trichrome vitiligo. J Am Acad Dermatol. 2000;42(4):589-96. https:\/\/doi.org\/10.1067\/mjd.2000.104896","DOI":"10.1067\/mjd.2000.104896"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"van Geel N, Speeckaert R, De Wolf J et al. Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol. 2012;167(5):1017-24. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11158.x","DOI":"10.1111\/j.1365-2133.2012.11158.x"},{"key":"ref13","unstructured":"Le Poole IC, van den Wijngaard RM, Westerhof W et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996;148(4):1219-28."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Elsherif R, Mahmoud WA, Mohamed RR. Melanocytes and keratinocytes morphological changes in vitiligo patients. A histological, immunohistochemical and ultrastructural analysis. Ultrastruct Pathol. 2022;46(2):217-235. https:\/\/doi.org\/10.1080\/01913123.2022.2044946","DOI":"10.1080\/01913123.2022.2044946"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"de Schrijver S, Theate I, Vanhooteghem O. Halo nevi are not trivial: about 2 young patients of regressed primary melanoma that simulates halo nevi. Case Rep Dermatol Med. 2021;2021:6672528. https:\/\/doi.org\/10.1155\/2021\/6672528","DOI":"10.1155\/2021\/6672528"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Rao M, Young K, Jackson-Cowan L et al. Post-inflammatory hypopigmentation: review of the etiology, clinical manifestations, and treatment options. J Clin Med. 2023;12(3):1243. https:\/\/doi.org\/10.3390\/jcm12031243","DOI":"10.3390\/jcm12031243"},{"key":"ref17","unstructured":"Frydkj\u00e6r AG, de Fine Olivarius F, M\u00f8ller MP. Sen debut af vitiligo som f\u00f8rste tegn p\u00e5 disseminering af moderm\u00e6rkekr\u00e6ft. Ugeskr L\u00e6ger. 2023;185:V09220537"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Sasaki M, Kondo M, Sato K et al. Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism. Pigment Cell Melanoma Res. 2014;27(5):754-63. https:\/\/doi.org\/10.1111\/pcmr.12269","DOI":"10.1111\/pcmr.12269"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Pollock S, Taylor S, Oyerinde O et al. The dark side of skin lightening: an international collaboration and review of a public health issue affecting dermatology. Int J Womens Dermatology. 2021;7(2):158-164. https:\/\/doi.org\/10.1016\/j.ijwd.2020.09.006","DOI":"10.1016\/j.ijwd.2020.09.006"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Liu RC, Consuegra G, Chou S, Pe\u00f1as PF. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol. 2019;44(6):643-646. https:\/\/doi.org\/10.1111\/ced.13867","DOI":"10.1111\/ced.13867"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Kokandi AA. Vitiligo appearing after oral isotretinoin therapy for acne. Case Rep Dermatol Med. 2018;2018:3697260. https:\/\/doi.org\/10.1155\/2018\/3697260","DOI":"10.1155\/2018\/3697260"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen MG, Toyserkani NM, Egeberg A, S\u00f8rensen JA. Risk of skin cancer in patients with vitiligo in Denmark: a nationwide cohort study. JAAD Int. 2020;1(1):31-38. https:\/\/doi.org\/10.1016\/j.jdin.2020.03.004","DOI":"10.1016\/j.jdin.2020.03.004"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Seneschal J, Boniface K. Vitiligo: current therapies and future treatments. Dermatol Pract Concept. 2023;13(4S2):e2023313S. https:\/\/doi.org\/10.5826\/dpc.1304S2a313S","DOI":"10.5826\/dpc.1304S2a313S"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Narayan VS, Uitentuis SE, Luiten RM et al. Patients' perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatology Venereol. 2021;35(3):744-748. https:\/\/doi.org\/10.1111\/jdv.16927","DOI":"10.1111\/jdv.16927"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Seneschal J, Duplaine A, Maillard H et al. Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. J Invest Dermatol. 2021;141(7):1728-1734. https:\/\/doi.org\/10.1016\/j.jid.2020.12.028","DOI":"10.1016\/j.jid.2020.12.028"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Wu CS, Yu CL, Wu CS et al. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol. 2004;13(12):755-63. https:\/\/doi.org\/10.1111\/j.0906-6705.2004.00221.x","DOI":"10.1111\/j.0906-6705.2004.00221.x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Coelho MMV, Matos TR, Apetato M. The dark side of the light: mechanisms of photocarcinogenesis. Clin Dermatol. 2016;34(5):563-70. https:\/\/doi.org\/10.1016\/j.clindermatol.2016.05.022","DOI":"10.1016\/j.clindermatol.2016.05.022"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Rosmarin D, Passeron T, Pandya AG et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-1455. https:\/\/doi.org\/10.1056\/nejmoa2118828","DOI":"10.1056\/NEJMoa2118828"},{"key":"ref29","unstructured":"ClinicalTrials.gov. Vitiligo phase 2 or 3 studies. U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/search?cond=vitiligo&aggFilters=phase:3%202 (20. aug 2024)"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:56:42Z","timestamp":1754485002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V10240662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v10240662","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}